Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3839)
All Articles published online
|
Sep 21, 2008 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Lu YY, Jing DD, Xu M, Wu K, Wang XP. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line. World J Gastroenterol 2008; 14(35): 5403-5411 [PMID: 18803351 DOI: 10.3748/wjg.14.5403] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i35/5403.htm |
| Number | Citing Articles |
| 1 |
LIN WANG, ZHI-XIA ZHU, WEN-YING ZHANG, WEI-MIN ZHANG. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells. Experimental and Therapeutic Medicine 2011; 2(5): 969 doi: 10.3892/etm.2011.293
|
| 2 |
Jana Jandova, Jean‐Philippe Galons, David L. Dettman, Georg T. Wondrak. Systemic deuteration of SCID mice using the water‐isotopologue deuterium oxide (D2O) inhibits tumor growth in an orthotopic bioluminescent model of human pancreatic ductal adenocarcinoma. Molecular Carcinogenesis 2023; 62(5): 598 doi: 10.1002/mc.23509
|
| 3 |
Sandy Vrignaud, José Hureaux, Séverine Wack, Jean-Pierre Benoit, Patrick Saulnier. Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride. International Journal of Pharmaceutics 2012; 436(1-2): 194 doi: 10.1016/j.ijpharm.2012.06.026
|
| 4 |
M. Noorani, N. Azarpira, K. Karimian, H. Heli. Erlotinib-loaded albumin nanoparticles: A novel injectable form of erlotinib and its in vivo efficacy against pancreatic adenocarcinoma ASPC-1 and PANC-1 cell lines. International Journal of Pharmaceutics 2017; 531(1): 299 doi: 10.1016/j.ijpharm.2017.08.102
|
| 5 |
Tianxiao Wang, Jingxuan Yang, Jianwei Xu, Jian Li, Zhe Cao, Li Zhou, Lei You, Hong Shu, Zhaohui Lu, Huihua Li, Min Li, Taiping Zhang, Yupei Zhao. CHIP is a novel tumor suppressor in pancreatic cancer and inhibits tumor growth through targeting EGFR. Oncotarget 2014; 5(7): 1969 doi: 10.18632/oncotarget.1890
|
| 6 |
Jin Jiang, Zuguo Yuan, Yiqing Sun, Yuan Bu, Wenfeng Li, Zhenghua Fei. Ginsenoside Rg3 enhances the anti-proliferative activity of erlotinib in pancreatic cancer cell lines by downregulation of EGFR/PI3K/Akt signaling pathway. Biomedicine & Pharmacotherapy 2017; 96: 619 doi: 10.1016/j.biopha.2017.10.043
|
| 7 |
Davoud Asgari, Ayuob Aghanejad, Javid Shahbazi Mojarrad. An Improved Convergent Approach for Synthesis of Erlotinib, a Tyrosine Kinase Inhibitor, via a Ring Closure Reaction of Phenyl Benzamidine Intermediate. Bulletin of the Korean Chemical Society 2011; 32(3): 909 doi: 10.5012/bkcs.2011.32.3.909
|
| 8 |
Shannon M. Gallagher-Colombo, Joann Miller, Keith A. Cengel, Mary E. Putt, Sergei A. Vinogradov, Theresa M. Busch. Erlotinib Pretreatment Improves Photodynamic Therapy of Non–Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms. Cancer Research 2015; 75(15): 3118 doi: 10.1158/0008-5472.CAN-14-3304
|
| 9 |
Jasmine G. Lee, Reen Wu. Erlotinib-Cisplatin Combination Inhibits Growth and Angiogenesis through c-MYC and HIF-1α in EGFR-Mutated Lung Cancer In Vitro and In Vivo. Neoplasia 2015; 17(2): 190 doi: 10.1016/j.neo.2014.12.008
|
| 10 |
Xiaoyu Yang, Yi Xu, Amanda Brooks, Bin Guo, Keith W. Miskimins, Steven Y. Qian. Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ω-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs. Free Radical Biology and Medicine 2016; 97: 342 doi: 10.1016/j.freeradbiomed.2016.06.028
|